Immunological approaches for the treatment of prostate cancer.
Publication/Presentation Date
2-1-1998
Abstract
Conventional therapies for patients with early-stage relapsed prostate cancer often do not provide an acceptable quality of life. These patients often have increasing PSAs as the sole manifestation of their disease recurrence and represent a unique subgroup of patients for whom alternative treatment strategies are needed. The patients are asymptomatic and may be an appropriate population for targeted immunological approaches. Vaccine therapies, based on synthetically constructed, naturally occurring prostate-associated antigens or genetically modified immune cells, offer exciting new approaches toward treating this disease with resulting antitumor effects and minimal toxicities. The results of clinical trials using these technologies reinforces the use of immunological approaches for the treatment of prostate cancer.
Volume
16
Issue
1
First Page
53
Last Page
59
ISSN
1081-0943
Published In/Presented At
Slovin, S. F., Kelly, W. K., & Scher, H. I. (1998). Immunological approaches for the treatment of prostate cancer. Seminars in urologic oncology, 16(1), 53–59.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
9508084
Department(s)
Administration and Leadership
Document Type
Article